絞り込み

16603

広告

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.

著者 Soria JC , Felip E , Cobo M , Lu S , Syrigos K , Lee KH , Göker E , Georgoulias V , Li W , Isla D , Guclu SZ , Morabito A , Min YJ , Ardizzoni A , Gadgeel SM , Wang B , Chand VK , Goss GD ,
Lancet Oncol.2015 Jul 3 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (227view , 0users)

Full Text Sources

Medical

Miscellaneous

Other Literature Sources

There is a major unmet need for effective treatments in patients with squamous cell carcinoma of the lung. LUX-Lung 8 compared afatinib (an irreversible ErbB family blocker) with erlotinib (a reversible EGFR tyrosine kinase inhibitor), as second-line treatment for patients with advanced squamous cell carcinoma of the lung.
PMID: 26156651 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード